Chen Runzhen, Liu Chen, Zhou Peng, Tan Yu, Sheng Zhaoxue, Li Jiannan, Zhou Jinying, Chen Yi, Song Li, Zhao Hanjun, Yan Hongbing
Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, China.
Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, 167 Beilishi Rd, Xicheng District, 100037, Beijing, China.
Thromb J. 2021 May 7;19(1):30. doi: 10.1186/s12959-021-00281-y.
Associations between D-dimer and outcomes of patients with acute coronary syndromes (ACS) remain controversial. This study aimed to investigate the prognostic value of D-dimer in ACS patients treated by percutaneous coronary intervention (PCI).
In this observational study, 3972 consecutive patients with ACS treated by PCI were retrospectively recruited. The X-tile program was used to determine the optimal D-dimer thresholds for risk stratifications. Cox regression with multiple adjustments was used for outcome analysis. Restricted cubic spline (RCS) analysis was performed to assess the dose-response association between D-dimer and outcomes. The C-index was calculated to evaluate the additional prognostic value of D-dimer when added to clinical risk factors and commonly used clinical risk scores, with internal validations using bootstrapping methods. The primary outcome was all-cause death.
During a median follow-up of 720 days, 225 deaths occurred. Based on the thresholds generated by X-tile, ACS-PCI patients with median (420-1150 ng/mL, hazard ratio [HR]: 1.58, 95 % confidence interval [CI]: 1.14-2.20, P = 0.007) and high (≥ 1150 ng/mL, HR: 1.98, 95 % CI: 1.36-2.89, P < 0.001) levels of D-dimer showed substantially higher risk of death compared to those with low D-dimer (< 420 ng/mL). RCS analysis depicted a constant relation between D-dimer and various outcomes. The addition of D-dimer levels significantly improved risk predictions for all-cause death when combined with the fully adjusted models (C-index: 0.853 vs. 0.845, P = 0.021), the GRACE score (C-index: 0.826 vs. 0.814, P = 0.027), and the TIMI score (C-index: 0.804 vs. 0.776, P < 0.001). The predicted mortality at the median follow-up (two years) was 1.7 %, 5.2 %, and 10.9 % for patients with low, median, and high D-dimer, respectively, which was well matched with the observed mortality (low D-dimer group: 1.2 %, median D-dimer group: 5.2 %, and high D-dimer group: 12.6 %).
For ACS patients treated by PCI, D-dimer level was an independent predictor for adverse outcomes, and provided additional prognostic value when combined with clinical risk factors and risk scores. Risk stratifications based on D-dimer was plausible to differentiate ACS-PCI patients with higher risk of death.
D - 二聚体与急性冠状动脉综合征(ACS)患者预后之间的关联仍存在争议。本研究旨在探讨D - 二聚体在接受经皮冠状动脉介入治疗(PCI)的ACS患者中的预后价值。
在这项观察性研究中,回顾性纳入了3972例连续接受PCI治疗的ACS患者。使用X - tile程序确定风险分层的最佳D - 二聚体阈值。采用多因素调整的Cox回归进行预后分析。进行限制立方样条(RCS)分析以评估D - 二聚体与预后之间的剂量反应关系。计算C指数以评估将D - 二聚体添加到临床危险因素和常用临床风险评分中时的额外预后价值,并使用自助法进行内部验证。主要结局为全因死亡。
在中位随访720天期间发生了225例死亡。根据X - tile生成的阈值,D - 二聚体水平处于中位(420 - 1150 ng/mL,风险比[HR]:1.58,95%置信区间[CI]:1.14 - 2.20,P = 0.007)和高水平(≥1150 ng/mL,HR:1.98,95%CI:1.36 - 2.89,P < 0.001)的ACS - PCI患者与低D - 二聚体(<420 ng/mL)患者相比,死亡风险显著更高。RCS分析描绘了D - 二聚体与各种结局之间的恒定关系。当与完全调整模型(C指数:0.853对0.845,P = 0.021)、GRACE评分(C指数:0.826对0.814,P = 0.027)和TIMI评分(C指数:0.804对0.776,P < 0.001)联合使用时,D - 二聚体水平显著改善了全因死亡的风险预测。在中位随访(两年)时,低、中、高D - 二聚体患者的预测死亡率分别为1.7%、5.2%和10.9%,与观察到的死亡率(低D - 二聚体组:1.2%,中D - 二聚体组:5.2%,高D - 二聚体组:12.6%)非常匹配。
对于接受PCI治疗的ACS患者,D - 二聚体水平是不良结局的独立预测因素,并且与临床危险因素和风险评分联合使用时提供了额外的预后价值。基于D - 二聚体的风险分层对于区分死亡风险较高的ACS - PCI患者是合理的。